Authors
Denise Myshko is the editor of Formulary Watch.
Ajai Chari, MD, is an expert in hematologic oncology who cares for patients at University of California San Francisco Health.
Mark F. Pyfer, MD, is a board-certified ophthalmic surgeon at Northern Ophthalmic Associates in Jenkintown, Pennsylvania. He is also on the volunteer teaching faculty and medical staff at Wills Eye Hospital and Thomas Jefferson University. This commentary represents his own personal opinion.
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer
3
Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%
4
Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care
5


